Search

Abstract Objective This study explored the predictors of abemaciclib discontinuation, a cyclin-dependent kinase 4 and 6 inhibitor, in patients with breast cancer. Material and Methods Between November 2018 and March 2023, 147 patients with breast cancer treated with abemaciclib at Osaka Medical and Pharmaceutical University Hospital and Kindai University Nara Hospital were included. The exclusion criteria were as follows: lack of blood testing within 2 weeks prior to starting abemaciclib therapy, transfer to another facility after the commencement of abemaciclib therapy, and discontinuation of abemaciclib therapy due to the diagnosis of another cancer. The duration from the initiation of abemaciclib to discontinuation for any reason and to temporary suspension or dose reduction due to adverse events were analyzed as outcome variables using multivariate Cox regression analysis. Results Baseline weight

As a method for separating tritiated water from radioactively contaminated water, an additive was mixed into the contaminated water and their treatments of agitation/circulation and electrolytic was considered to improve of the separation efficiency. Carbide powder and ore (silica stone) powder were used as additives. The radioactivity concentration of the tritium-contaminated water (tritiated water; HTO) was 366 Bq/mL before treatment, however it obtained 333 Bq/mL and decreasing rate of 9.02%, and a high separation efficiency after treatment. Furthermore, in the reproducibility experiments (five times) using high content of HTO, the average HTO/H2O separation efficiency was obtained about 5.59% indicating good reproducibility. The agitation/circulation treatment process was dissociated and ionized HTO, and was prepared colloidal particles by OT− and 3T+. In the electrolytic treatment process, the colloidal particles in HTO were deposited on the both electrodes applied DC voltage, and was efficiently removed tritium. These treatment processes using additives were found to be useful for removal of tritium.